Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2014. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to specific share transactions:
- Share Price: 1,414.00 pence per Ordinary Share and $45.90 per American Depositary Share (ADS).
- Transaction Type: Acquisition of shares via the re-investment of dividends under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Material Changes
The filing details increases in the notional interests of specific Directors and PDMRs in Ordinary Shares and ADSs. No material changes to the company's overall financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It notes that notional dividends accrued will be paid out proportionally based on the vesting of deferred annual bonus holdings following the relevant measurement period.
Investor Verification Checklist
- Verify the total number of shares acquired by Sir Andrew Witty (3,988 Ordinary Shares) and other listed executives.
- Confirm the share price of 1,414.00 pence per Ordinary Share against market data for October 6, 2014.
- Review the vesting schedule of the 2009 Deferred Annual Bonus Plan to understand future payout obligations.
- Note that this filing does not contain quarterly or annual financial performance data.